GlassScriptPhysician profile
Haig Najarian
NPI 1912010257
$12,712.63
in general payments reported to CMS, 2019-2025
42 companies · $2,019 in 2025
The $2,019 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,618 · 2020: $874 · 2021: $1,935 · 2022: $2,246 · 2023: $1,736 · 2024: $2,284 · 2025: $2,019.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,022 · Education: $16.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,022.36 |
| Education | $16.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,228.49 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,986.09 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $1,273.13 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $630.16 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Pfizer INC. | $608.31 | 2019-2025 | |
| Madrigal Pharmaceuticals | $426.52 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $385.81 | 2019-2025 | |
| Ardelyx, INC. | $336.85 | 2022-2025 | Ibsrela |
| Qol Medical, LLC | $296.50 | 2019-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $237.10 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $236.81 | 2019-2025 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $167.03 | 2019-2023 | Linzess |
| Phathom Pharmaceuticals, INC. | $156.14 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $119.80 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $119.04 | 2025 | Vowst, Zenpep |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haig Najarian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.